Soho Flordis International (SFI) is a global natural medicine company committed to identifying and developing leading natural medicines with the best evidence of effectiveness, quality and safety, and marketing them around the world.

SFI is focused on bringing its products to market through healthcare professionals with the endorsement of world class opinion leaders.


SFI is committed to ensuring that people globally have access to quality, innovative evidence based natural medicines. Therefore it is our aim that the safety and efficacy claims for our products are supported by specific clinical evidence. This higher standard enables the selection of safe, appropriate and effective treatments.
View our brands here.


SFI is building an international community of leading herbal and medical companies, experts, scientists and researchers.
View our partners here.


We are committed to further developing the evidence for our products.
View our research programs here.

latest news

Songha® Night launch in Pakistan

Thursday, April 23, 2015 - 15:33
Soho Flordis International is proud to announce that in April 2015, Ginsana SA increased its product portfolio in Pakistan through the joint launch of Songha® Night with local partner Chemifar International. The Ginsana SA range in Pakistan now includes Ginsana® capsules and tonic, Gincosan®, Ginsaflex and Songha® Night.

Ginsana taking part in Vitafoods Europe - The global nutraceutical event

Friday, April 17, 2015 - 15:24
Soho Flordis International is proud to announce that Ginsana SA will represent the SFI Group at Vitafoods Europe, the global nutraceutical event that attracts a focused audience of over 750 global suppliers and more than 14,000 senior manufacturers, distributors, researchers and scientists.

SFI Awarded Prestigious ABC’s Tyler Award Given Global Research Effort

Wednesday, March 4, 2015 - 12:33
In recognition of its ongoing commitment to research on natural products to help patients, Soho Flordis International (SFI) has been honored by the American Botanical Council (ABC).

SFI has joined “NSW Leaders”

Friday, February 27, 2015 - 14:10

KeenMind is the Focus of Attention in New Trial

Thursday, January 22, 2015 - 15:25
A new Australian trial will investigate the effects of KeenMind, a unique extract of Bacopa (Bacopa monnieri) CDRI 08, on hyperactivity, inattention and cognition in boys aged between 6 and 14 years.